Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China.
GLP-1 receptor agonist (GLP-1 RA)
Insulin
Obesity
Time trade-off (TTO)
Type 2 diabetes mellitus (T2DM)
Journal
The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
01
11
2021
accepted:
12
04
2022
pubmed:
9
5
2022
medline:
8
3
2023
entrez:
8
5
2022
Statut:
ppublish
Résumé
Once-daily and once-weekly injectable glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) are established in obesity and type 2 diabetes mellitus (T2DM). In T2DM, both once-daily and once-weekly insulin are expected to be available. This study elicited utilities associated with these treatment regimens from members of the general public in the UK, Canada, and China, to quantify administration-related disutility of more-frequent injectable treatment, and allow economic modelling. Two anchor states (no pharmacological treatment), and seven treatment states (daily oral tablet and generic injectable regimens of variable frequency), with identical outcomes were tested A broadly representative sample of the general public in each country participated (excluding individuals with diabetes or pharmacologically treated obesity). An adapted Measurement and Valuation of Health protocol was administered 1:1 in web-enabled interviews by trained moderators: visual analogue scale (VAS) as a "warm-up", and time trade-off (TTO) using a 20-year time horizon for utility elicitation. A total of 310 individuals participated. The average disutility of once-daily versus once-weekly GLP-1 RA was - 0.048 in obesity and - 0.033 in T2DM; the corresponding average disutility for insulin was - 0.064. Disutilities were substantially greater in China, relative to UK and Canada. Within obesity and T2DM, more-frequent treatment health states had lower utility. Scores by VAS also followed a logical order. The generated utility values are suitable for use in modelling injectable therapy regimens in obesity and T2DM, due to the use of generic descriptions and assumption of equal efficacy. Future research could examine the reasons for greater administration-related disutility in China.
Identifiants
pubmed: 35526173
doi: 10.1007/s10198-022-01470-w
pii: 10.1007/s10198-022-01470-w
pmc: PMC9080344
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-196Informations de copyright
© 2022. The Author(s).
Références
Nauck, M.A., et al.: GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Mol. Metab. 46, 101102 (2021)
doi: 10.1016/j.molmet.2020.101102
pubmed: 33068776
Wilding, J.P., et al.: Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. (2021). https://doi.org/10.1056/NEJMoa2032183
doi: 10.1056/NEJMoa2032183
pubmed: 34192450
Sheahan, K.H., Wahlberg, E.A., Gilbert, M.P.: An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad. Med. J. 96(1133), 156–161 (2020)
doi: 10.1136/postgradmedj-2019-137186
pubmed: 31801807
Trujillo, J.M., Nuffer, W., Smith, B.A.: GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 12, 2042018821997320 (2021)
doi: 10.1177/2042018821997320
pubmed: 33767808
pmcid: 7953228
Buse, J.B., et al.: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(2), 221–228 (2020)
doi: 10.1007/s00125-019-05039-w
pubmed: 31853556
Spain, C.V., et al.: Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin. Ther. 38(7), 1653-1664. e1 (2016)
doi: 10.1016/j.clinthera.2016.05.009
pubmed: 27364806
Garcia-Perez, L.-E., et al.: Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 4(2), 175–194 (2013)
doi: 10.1007/s13300-013-0034-y
pubmed: 23990497
pmcid: 3889324
Polonsky, W.H., et al.: Patient perspectives on once-weekly medications for diabetes. Diabetes Obes. Metab. 13(2), 144–149 (2011)
doi: 10.1111/j.1463-1326.2010.01327.x
pubmed: 21199266
Best, J.H., et al.: Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet. Med. 26(7), 722–728 (2009)
doi: 10.1111/j.1464-5491.2009.02752.x
pubmed: 19573122
pmcid: 2776933
Tolley, K.: What are health utilities. Hayward Medical Communications (2009)
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 - Chapter 5: The reference case. https://www.nice.org.uk/process/pmg9/chapter/the-reference-case (2013)
Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada, 4th edn. https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf (2017)
International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic Guidelines Around The World - China Mainland. https://tools.ispor.org/PEguidelines/countrydet.asp?c=28&t=4 (2018)
Matza, L.S., et al.: Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health (2021). https://doi.org/10.1016/j.jval.2020.12.017
doi: 10.1016/j.jval.2020.12.017
pubmed: 34119079
Brazier, J., Rowen, D.: NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values [Internet] (2011)
Boye, K.S., et al.: Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy. J. Med. Econ. 22(8), 806–813 (2019)
doi: 10.1080/13696998.2019.1609482
pubmed: 31010349
Boye, K.S., et al.: Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12(3), 219–230 (2011)
doi: 10.1007/s10198-010-0224-8
pubmed: 20224930
Matza, L.S., et al.: Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv. Res. 17(1), 1–10 (2017)
doi: 10.1186/s12913-017-2648-7
Shen, X., et al.: The diabetes epidemic in China: an integrated review of national surveys. Endocr. Pract. 22(9), 1119–1129 (2016)
doi: 10.4158/EP161199.RA
pubmed: 27295015
pmcid: 5567749
Diabetes Canada. Clinical Practice Guidelines. https://www.diabetes.ca/health-care-providers/clinical-practice-guidelines/chapter-1#panel-tab_FullText (2018)
Diabetes UK. Number of people with diabetes reaches 4.7 million. https://www.diabetes.org.uk/about_us/news/new-stats-people-living-with-diabetes (2019)
Whitehead, S.J., Ali, S.: Health outcomes in economic evaluation: the QALY and utilities. Br. Med. Bull. 96(1), 5–21 (2010)
doi: 10.1093/bmb/ldq033
pubmed: 21037243
Oppe, M., et al.: EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics 34(10), 993–1004 (2016)
doi: 10.1007/s40273-016-0404-1
pubmed: 27084198
pmcid: 5023738
EuroQol. EQ-5D-3L | Valuation. https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/valuation/ (2021)
Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35, 1095–1108 (1997)
doi: 10.1097/00005650-199711000-00002
pubmed: 9366889
Matza, L.S., et al.: Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health 24(6), 812–821 (2021)
doi: 10.1016/j.jval.2020.12.017
pubmed: 34119079
Matza, L.S., et al.: Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Qual. Life Res. 30(7), 2033–2043 (2021)
doi: 10.1007/s11136-021-02808-2
pubmed: 33886044
pmcid: 8233232
Dennett, S.L., Boye, K.S., Yurgin, N.R.: The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 11(3), 478–486 (2008)
doi: 10.1111/j.1524-4733.2007.00260.x
pubmed: 18489671
Lin, H.-W., et al.: Valuation of the EQ-5D-5L in Taiwan. PLoS ONE 13(12), e0209344 (2018)
doi: 10.1371/journal.pone.0209344
pubmed: 30586400
pmcid: 6306233
Wang, P., et al.: Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese. Eur. J. Health Econ. 16(8), 857–863 (2015)
doi: 10.1007/s10198-014-0635-z
pubmed: 25260384
Jin, X., et al.: Is bad living better than good death? Impact of demographic and cultural factors on health state preference. Qual. Life Res. 25(4), 979–986 (2016)
doi: 10.1007/s11136-015-1129-x
pubmed: 26346987
Matza, L.S., et al.: Patient preferences and health state utilities associated with mealtime insulin concentrations among patients with diabetes in Italy. Diabetes Ther. 11(1), 319–330 (2020)
doi: 10.1007/s13300-019-00718-8
pubmed: 31760598
Rajan, N., et al.: Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg. Issues 9, 67–71 (2016)
doi: 10.1016/j.vhri.2015.11.006
pubmed: 27881263
Matza, L.S., et al.: Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual. Life Res. 16(7), 1251–1265 (2007)
doi: 10.1007/s11136-007-9226-0
pubmed: 17638121
Gelhorn, H., et al.: The burden of type 2 diabetes and the value of achieving near normoglycemia from the patient perspective. Diabetes Ther. 12(7), 1821–1837 (2021)
doi: 10.1007/s13300-021-01054-6
pubmed: 34043162
pmcid: 8155797
Gelhorn, H.L., et al.: Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes Obes. Metab. 15(9), 802–809 (2013)
doi: 10.1111/dom.12091
pubmed: 23464623
Brazier, J., et al.: Measuring and valuing health benefits for economic evaluation. Oxford University Press, Oxford (2017)
Office for National Statistics. 2011 Census. https://www.ons.gov.uk/census/2011census (2011)
Office for National Statistics. Employment in the UK: December 2019. https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/employmentintheuk/december2019 (2019)
Office for National Statistics. Highest level of qualification achieved by people living in UK regions, 2010 to 2018. https://www.ons.gov.uk/peoplepopulationandcommunity/educationandchildcare/adhocs/10516highestlevelofqualificationachievedbypeoplelivinginukregions2010to2018 (2019)
Office for National Statistics. Population estimates by marital status and living arrangements, England and Wales. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesbymaritalstatusandlivingarrangements (2019)
Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2018. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/latest (2019)
Statistics Canada. Highest level of educational attainment (detailed) by selected age groups 25 to 64, both sexes, % distribution 2016, Canada, provinces and territories, 2016 Census – 25% Sample data. https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/hlt-fst/edu-sco/Table.cfm?Lang=E&T=21&Geo=00&View=2&Age=2 (2017)
Organisation for Economic Co-operation and Development. Education at a Glance 2019 - People's Republic of China. https://www.oecd.org/education/education-at-a-glance/EAG2019_CN_CHN.pdf (2019)
Statista. Population distribution in China in 2020, by broad age group. https://www.statista.com/statistics/251524/population-distribution-by-age-group-in-china/ (2021)